TSXV - Delayed Quote • CAD Conavi Medical Corp. (CNVI.V) Follow Compare 0.8000 +0.0300 +(3.90%) At close: January 17 at 3:59:49 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Conavi Medical and Minnetronix Medical Publish In-Depth Collaboration Review TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the publication of a detailed review of its collaboration with U.S.-based Minnetronix, a world leader in high-precision medical device manufacturing. Published in the industry Conavi Medical Announces Grant of Stock Options TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”) announced that its board of directors (the “Board”) has approved grants of stock options (the “Stock Options”) pursuant to the terms of the Omnibus Equity Incentive Plan effective January 2nd, 2025. A total of 1,073,685 Stock Options have been awarded to directors, officers, employees and consultants of the Company. The Stock Options are exercisable at a price of $0.70 CAD per share ( Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights – Completed US$7.7 million financing and reverse takeover to take Company public – Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company to fully repay debt to that partner – U.S. FDA submission of Novasight 3.0 system on track for calendar 2025 TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on design Conavi Medical to Participate in the MedInvest MedTech, AI & Digital Health Conference – Marks first time as a public company that Conavi is presenting at an investor event – – Live webcast presentation on Wednesday, December 11ᵗʰ at 3:35 p.m. ET – TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its Chief Executive Officer, Thomas Looby, China's NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IP – Approval triggers fourth and final US$5.9 million milestone payment to Conavi Medical, which it will use to extinguish the promissory note owed by it to EOM – – Conavi Medical eligible to receive future tiered royalty payments, ranging from 5.0%-10.0%, on net EOM coronary imaging system sales in China – TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage company focused on designing, manufacturing, and marketing i Conavi Medical Inc. (CNVI) Opens the Market Toronto, Ontario--(Newsfile Corp. - December 5, 2024) - Thomas Looby, Chief Executive Officer, Conavi Medical Inc. (TSXV: CNVI) ("Conavi Medical" or the "Company"), and his team, joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange (TSX), to open the market to celebrate the Company's new listing on the TSX Venture Exchange.Cannot view this video? Visit:https://www.youtube.com/watch?v=MRgHpP1QmeYConavi Medical is focused on designing, manufacturing, and marketin JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies – Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries – – Company showcasing its Novasight technology this week at TCT 2024 – TORONTO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is Conavi Medical Corp. Engages ICP Securities Inc. for Automated Market Making Services TORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- CONAVI MEDICAL CORP. (TSXV: CNVI) (“CONAVI MEDICAL” or the “Company”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has engaged the services of ICP Securities Inc. (“ICP”) to provide automated market making services, including use of its proprietary algorithm, ICP Premium™, in compliance with the policies and Performance Overview Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return CNVI.V S&P/TSX Composite index YTD +23.08% +1.82% 1-Year -36.00% +19.67% 3-Year -36.00% +17.37%